CA3092579A1 - Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases - Google Patents
Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases Download PDFInfo
- Publication number
- CA3092579A1 CA3092579A1 CA3092579A CA3092579A CA3092579A1 CA 3092579 A1 CA3092579 A1 CA 3092579A1 CA 3092579 A CA3092579 A CA 3092579A CA 3092579 A CA3092579 A CA 3092579A CA 3092579 A1 CA3092579 A1 CA 3092579A1
- Authority
- CA
- Canada
- Prior art keywords
- 6alkyl
- compound
- chosen
- 6alkoxy
- recited
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637147P | 2018-03-01 | 2018-03-01 | |
| US62/637,147 | 2018-03-01 | ||
| PCT/US2019/020395 WO2019169326A1 (en) | 2018-03-01 | 2019-03-01 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3092579A1 true CA3092579A1 (en) | 2019-09-06 |
Family
ID=67767960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3092579A Pending CA3092579A1 (en) | 2018-03-01 | 2019-03-01 | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11028083B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3758698A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7305664B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111867584A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019226585A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020017541A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3092579A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019169326A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020017541A2 (pt) | 2018-03-01 | 2020-12-22 | Board Of Regents, The University Of Texas System | Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, método para inibição de prmt, método para modular expressão de gene, e método para tratamento de uma doença mediada por prmt |
| WO2022192527A1 (en) * | 2021-03-12 | 2022-09-15 | Board Of Regents, The University Of Texas System | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5002941A (en) | 1985-12-12 | 1991-03-26 | Smithkline Beecham Corporation | Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors |
| JP2004149429A (ja) * | 2002-10-29 | 2004-05-27 | Takeda Chem Ind Ltd | インドール化合物およびその用途 |
| EP2221053A1 (de) * | 2009-02-20 | 2010-08-25 | Albert-Ludwigs-Universität Freiburg | Pharmazeutische Zusammensetzung enthaltend Hemmstoffe der Proteinmethyltransferase I und deren Verwendung zur Behandlung von Tumorerkrankungen |
| US9593109B2 (en) * | 2011-08-26 | 2017-03-14 | Cymabay Therapeutics, Inc. | Bicyclic agonists of GPR131 and uses thereof |
| WO2014153172A1 (en) | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| US9133189B2 (en) * | 2013-03-14 | 2015-09-15 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| CA2903394C (en) * | 2013-03-14 | 2021-08-31 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| JP2016514164A (ja) | 2013-03-14 | 2016-05-19 | エピザイム,インコーポレイティド | アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用 |
| EP3363434A1 (en) * | 2013-03-14 | 2018-08-22 | Epizyme Inc | Arginine methyltransferase inhibitors and uses thereof |
| EP2970181B1 (en) * | 2013-03-14 | 2017-06-07 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| EP2970135B1 (en) * | 2013-03-14 | 2018-07-18 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| US9120757B2 (en) * | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US9394258B2 (en) * | 2013-03-14 | 2016-07-19 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| US20160039767A1 (en) | 2013-03-14 | 2016-02-11 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
| AU2015301196A1 (en) | 2014-08-04 | 2017-01-12 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| US20170283400A1 (en) | 2014-09-17 | 2017-10-05 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2016044576A1 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor |
| US20170280720A1 (en) * | 2014-09-17 | 2017-10-05 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2016044626A1 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
| WO2017136699A1 (en) | 2016-02-05 | 2017-08-10 | Epizyme, Inc | Arginine methyltransferase inhibitors and uses thereof |
| KR102148587B1 (ko) | 2016-02-23 | 2020-08-26 | 화이자 인코포레이티드 | 6,7-디히드로-5H-피라졸로[5,1-b][1,3]옥사진-2-카르복스아미드 화합물 |
| BR112020017541A2 (pt) | 2018-03-01 | 2020-12-22 | Board Of Regents, The University Of Texas System | Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, método para inibição de prmt, método para modular expressão de gene, e método para tratamento de uma doença mediada por prmt |
-
2019
- 2019-03-01 BR BR112020017541-2A patent/BR112020017541A2/pt not_active Application Discontinuation
- 2019-03-01 JP JP2020545293A patent/JP7305664B2/ja active Active
- 2019-03-01 WO PCT/US2019/020395 patent/WO2019169326A1/en not_active Ceased
- 2019-03-01 CA CA3092579A patent/CA3092579A1/en active Pending
- 2019-03-01 CN CN201980020505.5A patent/CN111867584A/zh active Pending
- 2019-03-01 US US16/290,675 patent/US11028083B2/en not_active Expired - Fee Related
- 2019-03-01 AU AU2019226585A patent/AU2019226585A1/en not_active Abandoned
- 2019-03-01 EP EP19761558.6A patent/EP3758698A4/en not_active Withdrawn
-
2021
- 2021-05-04 US US17/307,568 patent/US11725008B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020017541A2 (pt) | 2020-12-22 |
| EP3758698A1 (en) | 2021-01-06 |
| WO2019169326A1 (en) | 2019-09-06 |
| CN111867584A (zh) | 2020-10-30 |
| US11028083B2 (en) | 2021-06-08 |
| JP7305664B2 (ja) | 2023-07-10 |
| US20190270739A1 (en) | 2019-09-05 |
| AU2019226585A1 (en) | 2020-10-08 |
| US20230027126A1 (en) | 2023-01-26 |
| EP3758698A4 (en) | 2021-10-20 |
| US11725008B2 (en) | 2023-08-15 |
| JP2021514999A (ja) | 2021-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019263294B2 (en) | Substituted heterocyclic inhibitors of PTPN11 | |
| AU2019245403B2 (en) | Imidazopiperazine inhibitors of transcription activating proteins | |
| WO2019036641A1 (en) | HETEROCYCLIC INHIBITORS OF KINASE ATR | |
| US10745420B2 (en) | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase | |
| CN121399124A (zh) | Kras调节剂及其用途 | |
| US11560366B2 (en) | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease | |
| AU2017371084A1 (en) | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease | |
| WO2009032754A2 (en) | Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease | |
| CA2934011A1 (en) | Pyrazole derivatives and uses thereof as inhibitors of dlk | |
| WO2021108198A1 (en) | Inhibitors of receptor interacting protein kinase i for the treatment of disease | |
| EP3823604A1 (en) | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase | |
| AU2017321313A1 (en) | Inhibitors of dual leucine ziper (DLK) kinase for the treatment of disease | |
| US11725008B2 (en) | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | |
| WO2022192527A1 (en) | Ethanediamine-heterocycle derivatives as inhibitors of protein arginine methyltransferases | |
| CA3024706A1 (en) | Heterocyclic inhibitors of ptpn11 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250904 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251104 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251231 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260423 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260703 |